Cediranib: Difference between revisions
Content deleted Content added
nav |
ref format |
||
| Line 25: | Line 25: | ||
| routes_of_administration = Oral |
| routes_of_administration = Oral |
||
}} |
}} |
||
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s. |
'''Cediranib''' (tentative trade name '''Recentin'''), also known as AZD2171, is a potent [[kinase inhibitor|inhibitor]] of [[vascular endothelial growth factor]] (VEGF) receptor [[tyrosine kinase]]s.<ref name="pmid15899831">{{cite journal |author=Wedge SR, Kendrew J, Hennequin LF, ''et al'' |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res. |volume=65 |issue=10 |pages=4389–400 |year=2005 |month=May |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409 |url=http://cancerres.aacrjournals.org/cgi/pmidlookup?view=long&pmid=15899831}}</ref> |
||
It is being developed by [[AstraZeneca]] as a possible anti-cancer chemotherapeutic agent for oral administration. |
|||
Beginning in 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway. |
Beginning in 2007, it is undergoing [[Clinical trial#Phase I|Phase I]] [[clinical trial]]s for the treatment of [[Lung cancer#Non-small cell lung cancer|non-small cell]] [[lung cancer]], [[kidney cancer]], and [[colorectal cancer]] in adults, as well as tumors of the [[central nervous system]] in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway. |
||
| Line 31: | Line 33: | ||
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. |
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. |
||
== |
==References== |
||
{{reflist}} |
|||
*{{cite journal |author=Wedge S, Kendrew J, Hennequin L ''et al''. |title=AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer |journal=Cancer Res |volume=65 |issue=10 |pages=4389–400 |year=2005 |pmid=15899831 |doi=10.1158/0008-5472.CAN-04-4409}} |
|||
==External links== |
==External links== |
||
Revision as of 18:04, 25 January 2009
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628 |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.505 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
Cediranib (tentative trade name Recentin), also known as AZD2171, is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.[1]
It is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.
Beginning in 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment are also underway.
On February 27th, 2008, AstraZeneca announced that the use of Recentin in non-small cell lung cancer will not progress into phase III after failing to meet its main goal.
References
- ^ Wedge SR, Kendrew J, Hennequin LF; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. doi:10.1158/0008-5472.CAN-04-4409. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |